# Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

> **NCT01017575** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 55 (actual)

## Conditions studied

- Hepatitis C Infection

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Daclatasvir
- **DRUG:** Placebo
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01017575
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017575, "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01017575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*